Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454809 | 0.70 | — | — | |
| SCHEMBL7750501 | 0.69 | — | — | |
| SCHEMBL10605855 | 0.67 | CYP2C19 (0.44) | HSD17B10CYP2C19ALDH1A1BCHEPOLB | |
| SCHEMBL10455903 | 0.65 | — | — | |
| SCHEMBL1100011 | 0.64 | — | — | |
| SCHEMBL9314750 | 0.62 | ALDH1A1 (0.30) | HSD17B10ALDH1A1BCHEPOLBMAOA | |
| SCHEMBL10455724 | 0.60 | CYP2C19 (0.47) | CYP2C19 | |
| SCHEMBL363382 | 0.60 | CYP2C19 (0.52) | HSD17B10CYP2C19ALDH1A1BCHEPOLB | |
| SCHEMBL30775643 | 0.60 | — | — | |
| SCHEMBL20079635 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| WO-2012004567-A2 | FLUORINE RADIOLABELLING PROCESS | ISIS INNOVATION LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190529-A1 | Fluorine Radiolabelling Process | ESRRG, NR5A2, RXFP4 | HSD17B10 956/4885CYP2C19 587/4885ALDH1A1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.